The veterinary laboratory from Carros is finding its footing again on Monday, ten days after a difficult session following its half-yearly results. The rebound occurs in a quasi-stable SBF 120, which makes Virbac's progress particularly visible within the index.
A technical rebound below three moving averages still distant
The Virbac share gains 1.48% to 308 € during the session, after closing the previous session on Friday at 303.50 €. This rebound takes place in a still tense technical context: the security remains below its 20-day moving average at 312.65 € (gap of -1.49%), its 50-day moving average at 326.21 € (-5.58%) and its 200-day moving average at 345.65 € (-10.89%), three levels that form as many upside resistance levels. The RSI at 36 reflects a configuration still close to oversold, without crossing the threshold, which leaves room for a rebound but does not signal a confirmed trend reversal.
The support level at 302 € remains the reference low to monitor, while resistance at 332.50 € represents the next notable obstacle if the momentum continues. Over one month, the security is still down 4.64%, and over three months the loss exceeds 9%. The one billion euro share buyback program announced in June 2026 constitutes a contextual element likely to support the price in the medium term.
Solid half-yearly results but a security still under pressure since September
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Monday's rebound comes after a difficult session on September 18, during which the security dropped 5.5%, worst performer of the SBF 120, despite the publication of half-yearly results deemed solid. Organic growth for the first half of 2026 had reached 7.4%, and management had confirmed its annual targets by placing itself at the upper end of the growth range, with revenue targeted at approximately 1,574 million euros for the full fiscal year, according to guidance communicated when publishing results on July 20, 2026. Before this September episode, the security had already broken its support at 314 € in early September in a context of pressure on the Paris market. Today's session, which places Virbac among the strongest gainers of the SBF 120, marks a lull, but the security remains more than 10% below its 200-day moving average and maintains negative year-to-date performance of -1.75%.
Two funds moreover maintain declared net short positions on the security, a level that testifies to residual caution from certain institutional investors, without one being able to infer an affirmed downward trend. The support at 302 € remains the short-term reference not to be lost.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.